Compare Stocks: TSHA, HHH, LGND, and CGON

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGON CG Oncology	$68.69 +2.0%	$74.10	$35.80 ▼ $80.97	$6.02B	0.28	1.10 million shs	277,573 shs
HHH Howard Hughes	$71.75 +1.0%	$65.87	$60.09 ▼ $91.07	$4.27B	1.14	491,432 shs	557,410 shs
LGND Ligand Pharmaceuticals	$306.35 +1.1%	$291.44	$175.89 ▼ $326.63	$6.11B	1.14	270,660 shs	79,280 shs
TSHA Taysha Gene Therapies	$4.48 -3.3%	$5.62	$3.69 ▼ $7.30	$1.45B	1.19	2.97 million shs	1.88 million shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGON CG Oncology	0.00%	+0.34%	-9.76%	-2.71%	+69.21%
HHH Howard Hughes	0.00%	+3.30%	+10.88%	-5.14%	-16.25%
LGND Ligand Pharmaceuticals	0.00%	+0.48%	+6.08%	-5.45%	+67.39%
TSHA Taysha Gene Therapies	0.00%	-0.86%	-17.32%	-27.43%	-2.73%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGON CG Oncology	$68.69 +2.0%	$74.10	$35.80 ▼ $80.97	$6.02B	0.28	1.10 million shs	277,573 shs
HHH Howard Hughes	$71.75 +1.0%	$65.87	$60.09 ▼ $91.07	$4.27B	1.14	491,432 shs	557,410 shs
LGND Ligand Pharmaceuticals	$306.35 +1.1%	$291.44	$175.89 ▼ $326.63	$6.11B	1.14	270,660 shs	79,280 shs
TSHA Taysha Gene Therapies	$4.48 -3.3%	$5.62	$3.69 ▼ $7.30	$1.45B	1.19	2.97 million shs	1.88 million shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGON CG Oncology	0.00%	+0.34%	-9.76%	-2.71%	+69.21%
HHH Howard Hughes	0.00%	+3.30%	+10.88%	-5.14%	-16.25%
LGND Ligand Pharmaceuticals	0.00%	+0.48%	+6.08%	-5.45%	+67.39%
TSHA Taysha Gene Therapies	0.00%	-0.86%	-17.32%	-27.43%	-2.73%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGON CG Oncology	2.73	Moderate Buy	$87.78	31.37% Upside
HHH Howard Hughes	2.00	Hold	$79.00	9.51% Upside
LGND Ligand Pharmaceuticals	3.00	Buy	$337.89	10.43% Upside
TSHA Taysha Gene Therapies	3.00	Buy	$12.77	191.87% Upside

Current Analyst Ratings Breakdown

Latest TSHA, HHH, LGND, and CGON Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/25/2026	LGND Ligand Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$345.00
9/24/2026	LGND Ligand Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$358.00
9/23/2026	LGND Ligand Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$390.00 ➝ $397.00
9/21/2026	LGND Ligand Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B-) ➝ Buy (B)
9/21/2026	TSHA Taysha Gene Therapies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/17/2026	TSHA Taysha Gene Therapies	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform
9/14/2026	HHH Howard Hughes	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/14/2026	LGND Ligand Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$330.00
8/11/2026	LGND Ligand Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Buy (B-)
8/7/2026	CGON CG Oncology	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$81.00 ➝ $79.00
8/7/2026	CGON CG Oncology	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$82.00 ➝ $85.00

(Data available from 10/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGON CG Oncology	$4.04M	1,465.96	N/A	N/A	$9.33 per share	7.16
HHH Howard Hughes	$1.47B	2.92	$6.32 per share	11.41	$64.69 per share	1.12
LGND Ligand Pharmaceuticals	$268.09M	22.76	$7.93 per share	38.58	$51.68 per share	5.92
TSHA Taysha Gene Therapies	$9.77M	145.91	N/A	N/A	$0.90 per share	4.86

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGON CG Oncology	-$160.99M	-$2.69	N/A	N/A	N/A	-3,602.68%	-25.20%	-23.98%	11/13/2026 (Estimated)
HHH Howard Hughes	$123.90M	$4.94	14.60	18.03	N/A	12.31%	7.51%	2.41%	N/A
LGND Ligand Pharmaceuticals	$124.45M	$9.35	32.72	36.64	2.45	67.88%	20.06%	11.68%	11/5/2026 (Estimated)
TSHA Taysha Gene Therapies	-$109M	-$0.42	N/A	N/A	N/A	N/A	-56.19%	-41.84%	11/3/2026 (Estimated)

Latest TSHA, HHH, LGND, and CGON Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	TSHA Taysha Gene Therapies	-$0.1133	-$0.13	-$0.0167	-$0.13	$0.68 million	N/A
8/6/2026	Q2 2026	CGON CG Oncology	-$0.6642	-$0.90	-$0.2359	-$0.90	$0.36 million	$1.16 million
8/6/2026	Q2 2026	LGND Ligand Pharmaceuticals	$1.97	$2.37	+$0.40	$2.22	$61.30 million	$63.69 million
8/5/2026	Q2 2026	HHH Howard Hughes	$0.49	$2.68	+$2.19	$2.68	N/A	$1.12 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGON CG Oncology	N/A	N/A	N/A	N/A	N/A
HHH Howard Hughes	N/A	N/A	N/A	N/A	N/A
LGND Ligand Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TSHA Taysha Gene Therapies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGON CG Oncology	N/A	22.22	22.20
HHH Howard Hughes	1.35	2.31	2.31
LGND Ligand Pharmaceuticals	1.16	31.18	30.96
TSHA Taysha Gene Therapies	0.13	17.76	17.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGON CG Oncology	26.56%
HHH Howard Hughes	93.83%
LGND Ligand Pharmaceuticals	91.28%
TSHA Taysha Gene Therapies	77.70%

Insider Ownership

Company	Insider Ownership
CGON CG Oncology	4.80%
HHH Howard Hughes	47.70%
LGND Ligand Pharmaceuticals	5.60%
TSHA Taysha Gene Therapies	3.48%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGON CG Oncology	142	88.64 million	84.39 million	Optionable
HHH Howard Hughes	500	59.72 million	31.23 million	Optionable
LGND Ligand Pharmaceuticals	47	19.94 million	18.82 million	Optionable
TSHA Taysha Gene Therapies	99	325.83 million	314.50 million	Optionable

TSHA, HHH, LGND, and CGON Headlines

Recent News About These Companies

Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Down 5.4% - Time to Sell?

2 hours ago | americanbankingnews.com

Taysha Gene Therapies (NASDAQ:TSHA) Shares Down 5.4% - Should You Sell?

3 hours ago | marketbeat.com

Analyzing Amylyx Pharmaceuticals (NASDAQ:AMLX) and Taysha Gene Therapies (NASDAQ:TSHA)

October 5 at 3:45 AM | americanbankingnews.com

Head to Head Analysis: Artiva Biotherapeutics (NASDAQ:ARTV) vs. Taysha Gene Therapies (NASDAQ:TSHA)

October 4 at 12:14 AM | americanbankingnews.com

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - October 2, 2026

October 4 at 12:11 AM | biospace.comB

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

October 2 at 8:00 AM | globenewswire.com

Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting

October 1, 2026 | globenewswire.com

Taysha Gene Therapies (NASDAQ:TSHA) Shares Up 5.7% - Here's What Happened

September 28, 2026 | marketbeat.com

Taysha Gene Therapies (NASDAQ:TSHA) Earns Outperform Rating from Analysts at Wolfe Research

September 17, 2026 | marketbeat.com

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Recommendation of "Buy" from Analysts

September 12, 2026 | marketbeat.com

Taysha Gene Therapies: A Bull Case That Does Not Require The Fastest Approval

September 11, 2026 | seekingalpha.com

These 3 Risky Stocks Could Be Sitting on 100% Upside (TSHA)

...

September 7, 2026 | marketbeat.com

Wellington Management Group LLP Acquires 3,349,244 Shares of Taysha Gene Therapies, Inc. $TSHA

September 6, 2026 | marketbeat.com

Bank of New York Mellon Corp Purchases New Position in Taysha Gene Therapies, Inc. $TSHA

September 6, 2026 | marketbeat.com

Seven Fleet Capital Management LP Has $9.94 Million Holdings in Taysha Gene Therapies, Inc. $TSHA

September 5, 2026 | marketbeat.com

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

September 4, 2026 | globenewswire.com

Taysha Gene Therapies Earnings Call Highlights Pivotal Progress

August 23, 2026 | tipranks.com

Taysha Gene Therapies (TSHA) Q2 2026 Earnings Call

August 18, 2026 | finance.yahoo.com

Wells Fargo Issues a Buy Rating on Taysha Gene Therapies (TSHA)

August 14, 2026 | theglobeandmail.com

Taysha Gene Therapies (TSHA) After Rett Trial Progress And Catalent Expansion Is The Undervalued Case Stronger

August 13, 2026 | finance.yahoo.com

Taysha Gene Therapies, Inc.: Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 12, 2026 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

TSHA, HHH, LGND, and CGON Company Descriptions

CG Oncology NASDAQ:CGON

$68.57 +1.19 (+1.77%)

As of 04:00 PM Eastern

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Howard Hughes NYSE:HHH

$71.67 +0.63 (+0.88%)

As of 04:00 PM Eastern

Howard Hughes Holdings Inc., together with its subsidiaries, operates as a real estate development company in the United States. It operates in four segments: Operating Assets; Master Planned Communities (MPCs); Seaport; and Strategic Developments. The Operating Assets segment consists of developed or acquired retail, office, and multi-family properties along with other retail investments. Its MPCs segment develops, sells, and leases residential and commercial land designated for long-term community development projects in and around Las Vegas, Nevada; Houston, Texas; and Phoenix, Arizona. The Seaport segment is involved in the landlord operations, managed businesses, and events and sponsorships services of its restaurant, retail, and entertain properties in Pier 17, New York City; Historic Area/Uplands; and Tin Building, as well as in 250 Water Street and in the Jean-Georges restaurants. The Strategic Development segment develops and redevelops residential condominiums and commercial properties. It serves homebuilders. Howard Hughes Holdings Inc. was founded in 2010 and is headquartered in The Woodlands, Texas.

Ligand Pharmaceuticals NASDAQ:LGND

$306.79 +3.83 (+1.26%)

As of 04:00 PM Eastern

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

Taysha Gene Therapies NASDAQ:TSHA

$4.49 -0.14 (-3.13%)

As of 04:00 PM Eastern

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TSHA, HHH, LGND, and CGON Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TSHA, HHH, LGND, and CGON Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TSHA, HHH, LGND, and CGON Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

TSHA, HHH, LGND, and CGON Company Descriptions

CG Oncology NASDAQ:CGON

Howard Hughes NYSE:HHH

Ligand Pharmaceuticals NASDAQ:LGND

Taysha Gene Therapies NASDAQ:TSHA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TSHA, HHH, LGND, and CGON Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TSHA, HHH, LGND, and CGON Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TSHA, HHH, LGND, and CGON Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

TSHA, HHH, LGND, and CGON Company Descriptions

CG Oncology NASDAQ:CGON

Howard Hughes NYSE:HHH

Ligand Pharmaceuticals NASDAQ:LGND

Taysha Gene Therapies NASDAQ:TSHA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools